Combining Statin and SGLT2i for Ischemic Heart Disease Treatment
Official title: "The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
Run by Fayoum University · NCT06520891 · Data updated 2026-11-12
This study is testing if taking both a statin and an SGLT2i together can help people with ischemic heart disease manage their condition better than taking either medication alone.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Fayoum University Academic / other |
| Locations | 1 site (Al Fayyum, Faiyum Governorate) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | November 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | September 11, 2025 |
| Trial ID | NCT06520891 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are outpatients diagnosed with ischemic heart disease who are eligible for statin and SGLT2i therapy.
✕Probably not a fit
Patients with liver or renal dysfunction, fungal infections, coagulation disorders, or those on interacting medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effects of statin and SGLT2i combination therapy in patients with ischemic heart disease. Conducted at Fayoum University, it will involve 90 outpatients who will be divided into three groups: those receiving statin, those receiving SGLT2i, and those receiving both medications. Blood samples will be collected to measure serum levels of both drugs using HPLC, and laboratory tests will monitor cholesterol, triglycerides, and lipoprotein levels over three months. The study seeks to understand the interactions and effects of these medications on heart disease management.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies for patients with ischemic heart disease by optimizing medication combinations.
How similar studies have gone: While the combination of these therapies has been explored, this specific approach in ischemic heart disease is relatively novel and may provide new insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease, * They assessed the use of statin with SGLT2i. Exclusion Criteria: * We exclude patients with 1. liver dysfunction. 2. renal dysfunction. 3. fungal infection. 4. coagulation disorder. 5. Pts using drugs that interact with SGLT2i. 6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.
Where it's running
-
Asmaa mohamed abdelkader
Al Fayyum, Faiyum Governorate, Egypt Recruiting
Study contacts
- Study coordinator: Raghda Roshdy
- Email: Raghda.hussien@pharm.bsu.edu.eg
- Phone: 01010647666
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.